NCT05144698
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF, ALK, BRCA+, EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have exposure to an anti-PD-(L)1 therapeutic monoclonal antibody therapeutic in the most recent line of prior therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with cancer metastasis to the central nervous system, unless adequately treated
https://ClinicalTrials.gov/show/NCT05144698